Anti-DCD monoclonal antibody Made to order

The use of synthetic nitrogen fertilisers is one of the most important land management practices proposed to improve crop and pasture productivity. The use of such fertilisers in excess can lead to greenhouse gas (GHG) emissions, linked to climate change, as well as ammonia (NH3) emissions, linked to eutrophication and soil acidification.. This context is especially important in Brazil, which is responsible for a significant share of the food produced in the world. To assess the impact of the use of nitrogen fertilisers, we conducted a structured review of Brazilian studies on the emission of nitrous oxide (N2O; 11 studies) and ammonia volatilisation (NH3; 13 studies) from nitrogen fertiliser application. The current emission factors (EF) suggested by the IPCC for N2O and NH3 (1 and 11%, respectively) are lower than the mean values we found in our review (1.12 and 19%, respectively). Our results showed that non-urea fertilisers (ammonium nitrate or ammonium sulphate) had a lower emission factor (EF) for N2O (1.07 and 0.60%, respectively) and NH3 (3.17 and 14%, respectively) in comparison with urea. The use of nitrification and urease inhibitors resulted in a reduction of the EFs of N2O (74% lower) and NH3 (43% lower) when compared with the Urea EF. Urea is the most common fertiliser used in Brazil, and the change for non-urea fertilisers or the use of inhibitors could lead to a reduction of 23% in the total N2O inventory. The use of the new region-specific EFs results in an increase of 21% in the final N2O emission inventory.

Recipients of donation after circulatory death (DCD) LTs historically have an increased risk of graft failure. Antibody induction (AI) with antithymocyte globulin (ATG) or anti-interleukin 2 receptor (anti-IL2R) immunotherapy may decrease the incidence of graft failure by mitigating ischemia/reperfusion injury. A retrospective review of the United Network for Organ Sharing (UNOS) database for LTs between 2002 and 2015 was conducted to determine whether ATG or anti-IL2R AI was associated with graft survival in DCD. A secondary endpoint was postoperative renal function as measured by estimated glomerular filtration rate at 6 and 12 months. Among DCD recipients, ATG (hazard ratio [HR] = 0.71;P = 0.03), but not anti-IL2R (HR = 0.82;P = 0.10), was associated with a decrease in graft failure at 3 years when compared with recipients without AI. ATG (HR = 0.90;P = 0.02) and anti-IL2R (HR = 0.94;P = 0.03) were associated with a decreased risk of graft failure in donation after brain death (DBD) liver recipients at 3 years compared with no AI. When induction regimens were compared between DCD and DBD, only ATG (HR = 1.19;P = 0.19), and not anti-IL2R (HR = 1.49;P < 0.01) or no AI (HR = 1.77;P < 0.01), was associated with similar survival between DCD and DBD. In conclusion, AI therapy with ATG was associated with improved longterm liver allograft survival in DCD compared with no AI. ATG was associated with equivalent graft survival between DCD and DBD, suggesting a beneficial role of immune cell depletion in DCD outcomes.